JNJ-66525433

JNJ-66525433 is an investigational small molecule drug that was developed by Janssen, a subsidiary of Johnson & Johnson, for the treatment of immune system diseases and digestive system disorders, with a primary focus on ulcerative colitis. The drug advanced to Phase 1 clinical trials, where it was evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy participants and patients with ulcerative colitis. The development program included single and multiple ascending dose studies administered orally. However, the clinical trial (NCT04457960) was terminated before completion and further development has been discontinued. The specific molecular target or mechanism of action for JNJ-66525433 has not been publicly disclosed[1][2][3][4][5][8].